TGFB1 and Marfan syndrome: Specifically, the authors demonstrated that circulating TGF-β1 concentrations are elevated in MFS and decrease after the administration of losartan, beta-blocker therapy, or both, and therefore might serve as a prognostic and therapeutic marker in MFS patients with TAA.